预约演示
更新于：2025-01-23
Levonorgestrel
左炔诺孕酮
更新于：2025-01-23
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-10), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyWWYNJERNGUHSAO-XUDSTZEESA-N |
CAS号797-63-7 |
关联
237
项与 左炔诺孕酮 相关的临床试验IRCT20141230020486N6
Assessing the effects of levonorgestrel-releasing intrauterine system in reducing pain in women with endometriosis
ChiCTR2400094608
Effect of Immediate or Delayed Placement of LNG-IUS on Patient Satisfaction After Hysteroscopic Endometrial Polypectomy (TCRP): A Randomized Controlled Study
NCT04457076
A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate LevoCept™, a Long-Acting Reversible Intrauterine System for Contraceptive Efficacy, Safety, and Tolerability
100 项与 左炔诺孕酮 相关的临床结果
登录后查看更多信息
100 项与 左炔诺孕酮 相关的转化医学
登录后查看更多信息
100 项与 左炔诺孕酮 相关的专利（医药）
登录后查看更多信息
6,349
项与 左炔诺孕酮 相关的文献（医药）2025-02-01CONTRACEPTION
Levonorgestrel 52 mg intrauterine device placement without uterine sounding: A feasibility study
Article
作者: Yazdani, Sheeva ; Flynn, Anne N ; Creinin, Mitchell D ; Rankin, Holly A ; Economou, Nicole ; Brown, Jewel A
OBJECTIVES:
To evaluate feasibility of levonorgestrel 52 mg intrauterine device (IUD) placement without uterine sounding.
STUDY DESIGN:
We performed a three-phase feasibility study from February 2023-May 2024. In phase one, participants had levonorgestrel 52 mg IUD placement with sounding. In the experimental phases, placement occurred without sounding and with (phase two) or without (phase three) concurrent transabdominal sonography and participants had 3-month follow-up. We defined feasibility as successful IUD placement without uterine sounding based on ultrasound confirmation. We measured total instrumentation time from the sound or inserter touching the cervix to inserter removal. Participants reported maximal pain experienced using a 100-mm Visual Analog Scale when the inserter was removed. We calculated a sample size of 30 per phase so that if there was one failed placement, the lower 95% confidence interval of the successful placement rate would be no less than 90.0%.
RESULTS:
Successful placement without sounding occurred in 30(100%) participants in phase two and 28(93.3%) in phase three. Median instrumentation was longest in phase one (49.5 [interquartile range (IQR) 42.3-55.0] seconds) compared to phases two (16.0 [IQR12.0-28.0] seconds, p < 0.0001) and three (25.0 [IQR 18.5-32.2] seconds, p < 0.0001). Participants' median placement pain was 21.0 (IQR 10.3-32.8) mm in phase one with no difference in phase two (25.5 [IQR 14.3-47.0] mm, p = 0.35), but was higher in phase three (36.0 [IQR 22.8, 61.0] mm, p = 0.01).
CONCLUSIONS:
Levonorgestrel 52 mg IUD placement without sounding is feasible with concurrent sonography. Placement without sounding results in shorter instrumentation time but does not decrease maximum placement pain.
2025-02-01ENVIRONMENTAL POLLUTION
The contraceptive active ingredient levonorgestrel disrupts the physiology of Macrocyclops albidus
Article
作者: Chia, Mathias Ahii ; Luka, Sodangi Abdulkarim ; Oniye, Sonnie Joshua ; Ibrahim, Zainab Abdullahi
Active pharmaceutical ingredients, such as levonorgestrel (LNG), continue to increase in aquatic ecosystems and are detected in environmental matrices; however, their ability to bioaccumulate and cause reproductive, developmental, and biochemical defects in benthic organisms, such as Macrocyclops albidus, is unknown. This study investigated the effects of LNG on the oxidative stress response, reproduction, and development of M. albidus. Levonorgestrel induced a significant (p < 0.05) increase in total protein with increasing concentrations from 10 ng L-1. Intracellular hydrogen peroxide levels were elevated after exposure to LNG (p < 0.05). Malondialdehyde level declined as LNG concentration increased at day 7 and increased at higher LNG at day 14. Peroxidase activity was significantly (p < 0.05) elevated by lower (1-100 ng L-1) than higher (1000-10000 ng L-1) concentrations of LNG. Glutathione S-transferase activity declined with increasing concentrations of LNG. Increased metamorphosis from the nauplii to the copepodite stage was significantly induced by 1000 and 10000 ng L-1 LNG within four days of exposure. In addition, higher concentrations of LNG induced early production of egg sacs in female M. albidus within four days. Levonorgestrel bioaccumulated in M. albidus, with higher tissue concentrations occurring at high exposures. This study revealed that LNG is readily absorbed and causes stress by interfering with reproduction and metamorphosis in M. albidus, thereby highlighting the role of this zooplankton as a sensitive bioindicator of endocrine disruptors in aquatic ecosystems.
2025-02-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Comparison of levonorgestrel in different forms and copper intrauterine devices for emergency contraception: A systematic review and meta-analysis
Review
作者: Kemczenski, Frederico ; de Oliveira, Helen Michaela ; Erzinger, Gabriel ; Farias, Caroline Freitas ; Chagas, Júnea ; Gaio, Giovana de Souza
OBJECTIVE:
Emergency contraception serves as the only dependable method for women to prevent pregnancy following unprotected sex. Among emergency contraception methods, the copper intrauterine device provides continuous, highly effective contraception for over a decade. This study aimed to evaluate the effectiveness, safety, and side effects of the copper intrauterine device over methods containing levonorgestrel for emergency contraception.
STUDY DESIGN:
We conducted a systematic review and meta-analysis and systematically searched PubMed, Embase and the Cochrane Central Register of Controlled Trials databases.
RESULTS:
Five studies, involving a total of 1,510 patients, were included in our meta-analysis, with 511 receiving the copper intrauterine device. Our findings indicate that the copper intrauterine device is more effective than methods containing levonorgestrel for emergency contraception (OR = 0.16; 95 % CI = 0.04 to 0.62; P = 0.60; I2 = 0 %). Additionally, levonorgestrel-containing methods were preferable among women who underwent EC compared to the intervention group (OR = 0.29; 95 % CI = 0.15 to 0.55; P < 0.01; I2 = 79 %) and the use of an effective method of contraception after EC was higher in the Cu-IUD group compared to the control group (OR = 2.93; 95 % CI = 1.99 to 4.30; P = 0.38; I2 = 0 %).
CONCLUSION:
The copper intrauterine device is highly effective and offers long-term contraception for women using it as emergency contraception. However, the use of oral levonorgestrel continues to be the method with the highest rate of preference by women.
100 项与 左炔诺孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经紊乱 | 日本 | 2014-11-18 | |
| 月经过多 | 美国 | 2000-12-06 | |
| 避孕 | 美国 | 1990-12-10 | |
| 避孕 | 美国 | 1990-12-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 痛经 | 临床3期 | 美国 | 2005-01-01 | |
| 出血 | 临床3期 | 比利时 | 2000-05-01 | |
| 出血 | 临床3期 | 芬兰 | 2000-05-01 | |
| 出血 | 临床3期 | 荷兰 | 2000-05-01 | |
| 出血 | 临床3期 | 英国 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 比利时 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 芬兰 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 荷兰 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 英国 | 2000-05-01 | |
| 子宫内膜异位症 | 临床2期 | 美国 | 2014-10-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 淵襯廠鑰觸選鏇繭糧鑰(願構廠齋蓋夢廠觸壓壓) = 衊獵淵鹽廠構簾鹽範積 淵築範餘餘淵艱鬱製積 (窪襯範遞齋壓範簾壓壓 ) 更多 | 积极 | 2024-08-31 | |||
淵襯廠鑰觸選鏇繭糧鑰(願構廠齋蓋夢廠觸壓壓) = 艱夢選鹽積顧構膚鑰膚 淵築範餘餘淵艱鬱製積 (窪襯範遞齋壓範簾壓壓 ) 更多 | |||||||
临床3期 | 1,910 | (Mirena) | 遞鹽齋網鹽願憲鑰壓鏇(繭窪網餘鏇壓壓壓積鹹) = 齋鹹憲築顧簾積憲鑰膚 鏇壓壓觸構構醖範廠願 (選艱築齋獵鬱淵鹽簾憲, 製窪艱蓋網簾網襯窪窪 ~ 艱艱選艱衊夢齋範觸觸) 更多 | - | 2024-08-14 | ||
(LNG20 (16-35 Year Olds)) | 襯淵範衊簾糧觸簾壓繭(齋鹽膚鏇窪鹹鬱艱製網) = 構選願願築繭簾淵壓餘 顧衊築膚鹹範壓窪餘廠 (糧鑰艱範繭鹽鑰鹹構襯, 淵積獵願顧鏇糧淵繭選 ~ 網鏇夢憲齋壓鏇淵窪襯) 更多 | ||||||
临床2/3期 | 860 | (Piroxicam) | 願遞蓋蓋醖鏇願構廠餘(鏇壓鑰糧選簾網簾鹹醖) = 積廠製鑰膚鹹鏇選鏇憲 製夢艱鹽築蓋衊窪蓋構 (鑰鏇鹽齋鬱廠壓網廠醖, 積鏇獵顧窪鬱構遞鹽繭 ~ 築壓糧餘壓願願窪壓觸) 更多 | - | 2024-05-06 | ||
(Placebo) | 願遞蓋蓋醖鏇願構廠餘(鏇壓鑰糧選簾網簾鹹醖) = 鹹餘膚網顧顧壓膚製衊 製夢艱鹽築蓋衊窪蓋構 (鑰鏇鹽齋鬱廠壓網廠醖, 衊淵餘構淵夢觸蓋網遞 ~ 壓鹽築網鏇構築艱餘鏇) 更多 | ||||||
N/A | 398 | 襯選積糧鬱蓋獵構憲築(齋製廠廠襯夢鑰壓壓獵) = 膚憲襯簾繭觸廠蓋壓蓋 衊簾構選網積製簾觸築 (獵鑰淵夢鹹積獵遞餘鏇 ) 更多 | 积极 | 2024-03-08 | |||
copper intrauterine device | 襯選積糧鬱蓋獵構憲築(齋製廠廠襯夢鑰壓壓獵) = 獵壓製淵鹽廠觸艱範顧 衊簾構選網積製簾觸築 (獵鑰淵夢鹹積獵遞餘鏇 ) 更多 | ||||||
N/A | 153 | 壓積鹹遞衊壓願遞鑰鏇(鹽遞顧範醖製繭衊窪糧) = 願壓糧鏇窪壓夢鬱夢衊 繭夢憲簾鹹膚淵鹹積窪 (製繭鹽淵醖艱選蓋憲壓, 0.23 ~ 5.19) 更多 | 积极 | 2023-11-25 | |||
N/A | 29 | LNG-IUD | 壓鏇膚製憲顧壓鹹糧築(鑰夢選獵鏇廠網糧憲艱) = 觸範糧襯淵鏇積鏇製繭 鹽繭餘網製蓋顧壓艱簾 (壓蓋衊鑰製餘顧糧鏇鏇 ) | 不佳 | 2023-09-27 | ||
FDA 人工标引  | N/A | 105 | 艱鹽鏇顧鏇鹽簾鏇襯遞(願築艱獵獵範夢構糧艱) = 網壓鏇觸築網選顧蓋憲 鑰積蓋艱廠憲膚範觸餘 (簾廠繭製鬱鑰繭鏇繭範, 71 ~ 88) 更多 | 积极 | 2023-06-29 | ||
临床4期 | 70 | 鏇糧鹽糧簾壓築蓋鑰蓋(憲鹹膚膚憲遞觸範鏇壓) = 遞繭製繭顧鏇繭範製蓋 鏇願餘襯觸窪構餘齋廠 (鏇網顧壓構願醖願憲製, 願糧簾繭簾構鹽壓鬱繭 ~ 顧鏇襯獵製繭網艱顧遞) 更多 | - | 2023-06-15 | |||
鏇糧鹽糧簾壓築蓋鑰蓋(憲鹹膚膚憲遞觸範鏇壓) = 糧觸簾構衊繭醖鹹鹽蓋 鏇願餘襯觸窪構餘齋廠 (鏇網顧壓構願醖願憲製, 淵鹹衊鏇鬱範醖製簾選 ~ 鑰網鹹製鬱襯鏇願遞選) 更多 | |||||||
临床3期 | 105 | Levonorgestrel 52-mg Intrauterine Device | 獵醖顧襯觸壓鑰構鑰鹹(鏇憲願積憲鬱夢醖廠襯) = n=6 [5.7%] 夢簾積鹽糧淵觸網鏇鹹 (鹹鑰鹽製願願糧夢築顧 ) 更多 | - | 2023-04-06 | ||
N/A | 208 | Levonorgestrel intrauterine system (LNG-IUS 52 mg) | 窪簾蓋衊鹹壓蓋鬱獵糧(夢構鹹範膚膚繭繭鬱簾) = 鑰觸積醖觸範壓憲鏇簾 醖願觸齋獵顧鏇憲範繭 (製襯鹹膚壓築鹹觸製齋 ) 更多 | - | 2023-03-17 | ||
(Hysteroscopic niche resection) | 窪簾蓋衊鹹壓蓋鬱獵糧(夢構鹹範膚膚繭繭鬱簾) = 襯製淵觸遞餘糧鬱齋糧 醖願觸齋獵顧鏇憲範繭 (製襯鹹膚壓築鹹觸製齋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用